[Clinical effectiveness of Marvelon]

L Marianowski, Barbara Grzechocińska, B Grzechocińska
Ginekologia polska · 1995 · vol. 66(5) , pp. 294–6 · PMID:8522228 · W127674063
Non-randomised trial OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-09 ⓘ

Marvelon, a new contraceptive pill, was well-tolerated with low side effects, regular cycles, unchanged bleeding, no impact on weight or blood pressure, and a favorable lipid profile in 32 women over 6 cycles, achieving a Pearl Index of 0.0.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Clinical results of a new contraceptive pills--Marvelon (Organon) were studied. 32 women, ages 30 +/- 5 years, participated in the study during at least 6 cycles. Marvelon was good tolerated and subjective side-effects were very low. The cycles were regular, duration of withdrawal bleeding was 3-5 days and the amount of the blood lost were unchanged or milder. Marvelon didn't affect body weight and blood pressure. Favourable lipid profile--increased a mean level of HDL-Cholesterol and decreased a mean level of LDL-Cholesterol were noticed. Pearl Index was 0,0.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Desogestrel Desogestrel Adult Cholesterol, HDL Cholesterol, HDL Cholesterol, HDL Cholesterol, LDL Cholesterol, LDL Cholesterol, LDL Female Humans Menstrual Cycle Menstrual Cycle

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:59:37.277143+00:00
License: CC0 · commercial use OK